Abeona Therapeutics 计划于2027年下半年提交新药临床试验申请并启动ABO-701首次人体研究

美股速递
May 13

Abeona Therapeutics Inc 宣布,其针对ABO-701的研究计划取得明确进展。该公司预期将在2027年下半年向监管机构提交新药临床试验(IND)申请,并随即启动该候选药物的首次人体临床研究。这一时间表标志着公司研发管线中这一重要项目进入了新的实质性阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10